One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
Its DirectDetect reagent eliminates RNA extraction for rapid deployment of Covid-19 tests in affected countries
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
The company operates in over eight cities and the start-up plans to expand its reach to over 100 non-metro cities in the next 18-24 months
The Mission will simplify hospital processes and will increase Ease of Living. Under this, every citizen will get a digital health ID and their health record will be digitally protected.
A high-value proposition recyclable film packed with industry-leading barrier and metal bond performance, sustainability quotient and U.S. FDA compliant
The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients
The company plans to launch its exclusive e-pharmacy and telemedicine services in India by December 2021
The company will leverage existing hospital and clinic partners’ infrastructure to build specialised `Experience Centres’ and facilitate a seamless, end-to-end secondary care surgery delivery. It will also offer healthcare financing
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
Subscribe To Our Newsletter & Stay Updated
